u/Personal_Pride_2238

The author highlights that A2 Gold Corp. has expanded its planned 2026 drill program at the Eastside Gold Project in Nevada to 30,000 metres, the largest in company history, designed to advance known mineralization and explore new high-impact targets. The company recently listed on the Börse Frankfurt to increase global visibility and euro-denominated access. No specific risk is stated.

Prairie Operating Co. is successfully integrating its DJ Basin acquisition, evidenced by strong Q3 EBITDA growth and improved operational efficiency. The company's extensive hedge book provides predictable cash flow, mitigating risks associated with increased leverage from the acquisition. A near-term catalyst is the production ramp-up to approximately 27k Boe/d.

The author argues PDS Biotechnology is a high-risk, high-reward bet on PDS0101, an immunotherapy targeting HPV16-positive head and neck cancer, a niche with rising incidence and limited treatment options. The stated catalyst is the company's request to amend the Phase 3 VERSATILE-003 protocol to add progression-free survival as a surrogate primary endpoint while retaining median overall survival for full approval, which if FDA-approved could shorten the trial timeline and deliver meaningful data sooner. Supporting evidence cited is the Phase 2 VERSATILE-002 median overall survival of 39.3 months versus historical outcomes, plus SITC 2025 data on the platform and the PDS0101 ADC IL-12 conjugate. The author's stated risks are going-concern funding risk without additional capital, debt covenant operating constraints, dilution, and heavy dependence on Phase 3 execution where any delay or failure would likely hit valuation materially.